Periodic piece

About a decade after an Arch Venture-led syndicate formed Ikaria Inc. to develop elemental reducing agents for critical care, the firm is going back for round two with the technology. Although the assets have been gathering dust for years, new owner Faraday Pharmaceuticals Inc. said the dearth of innovation in the critical care space means there is still a need for its products.

The technology originated in the lab of Mark Roth at the Fred Hutchinson Cancer Research Center. It involves using reduced forms of elements to treat conditions including limb ischemia and reperfusion injury. Roth is Faraday's president. ...